SURAKSHA DIAGNOSTIC LIMITED (SURAKSHA): SURAKSHA 52 Week High Streak: Consecutive High Analysis
- September 22, 2026
- Posted by: Harsh Piplani
- Category: News
SURAKSHA DIAGNOSTIC LIMITED (SURAKSHA) has now traded within 2% of its 52-week high for its second straight session, with the stock moving 5.18% across this streak. The latest peak stands at Rs 354.05, while the current price is Rs 353.45. The latest Univest figures confirm the price pattern, but they do not establish a company-specific catalyst for the continued move.
As of 22 September 2026 at 10:48 AM IST, the stock was above its previous close of Rs 349.65 after opening at Rs 349.45 and touching a low of Rs 344.85. Turnover stood at Rs 0.18 crore and market capitalisation at Rs 1,750.17 crore. For readers, the repeated-high pattern is more useful than a single-day print because it shows how the stock is behaving across sessions around its yearly high, rather than just one intraday move.
SURAKSHA 52 Week High Streak: Consecutive High Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 353.45 |
| Previous Close | Rs 349.65 |
| Today's Move | +Rs 3.8 (+1.09%) |
| Open | Rs 349.45 |
| High | Rs 354.05 |
| Low | Rs 344.85 |
| Turnover | Rs 0.18 crore |
| Market Capitalisation | Rs 1,750.17 crore |
SURAKSHA DIAGNOSTIC LIMITED (SURAKSHA) traded at Rs 353.45 versus the previous close of Rs 349.65, a rise of 1.09%. The stock opened at Rs 349.45, reached a high of Rs 354.05 and touched a low of Rs 344.85.
SURAKSHA share price today is trading at Rs 353.45, up Rs 3.80 or 1.09% from the previous close of Rs 349.65. The stock opened at Rs 349.45, moved between Rs 344.85 and Rs 354.05, and is now trading near the upper end of that range. That placement keeps the SURAKSHA share price in the same high-zone context that has defined the current streak.
For a stock news reader, the key point is not only the intraday range but the repeated proximity to the yearly high across consecutive sessions. The market capitalisation of Rs 1,750.17 crore places the company firmly in the listed diagnostics and healthcare space where relative valuation and execution quality often remain in focus. The move across the streak has been measured and not abrupt, which makes the back-to-back 52-week highs more notable as a pattern than as a one-off print.
SURAKSHA 52 Week High Streak: Consecutive High Analysis
SURAKSHA 52 Week High Streak has now extended into a second straight session, with the stock trading within 2% of its one-year high on both days. The cumulative move across the streak is 5.18%, which is the most important differentiator from a single-session high story. That cumulative reading helps frame the stock performance across the short run, rather than focusing only on the latest quote.
The current 52-week high is Rs 354.05, and the current price is Rs 353.45, keeping the stock just below that peak. In practical terms, the market is repeatedly placing SURAKSHA in the same narrow band around its yearly high, which is why this is being tracked as a consecutive 52-week high event. The latest numbers confirm the streak, but they do not by themselves explain why the stock has remained near the top of its range.
What the Repeated 52-Week Highs Show
The repeated 52-week highs show that SURAKSHA has sustained its position near the top of the past year’s trading range for more than one session. That matters because it shifts attention from a one-day move to the broader streak. The stock is not being discussed here as having made a fresh all-time high, and the data only supports a near 52-week high read, not a lifetime record statement.
For investors tracking SURAKSHA stock analysis, the main takeaway is that the price has remained close to the yearly high even after the first breakout-style session. The latest Univest figures confirm the pattern, but they do not confirm a company-specific trigger behind it. As a result, the streak should be read as a market data event first and a business interpretation only where separate company information is available.
SURAKSHA DIAGNOSTIC LIMITED (SURAKSHA) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 1,750.17 crore |
| P/E Ratio | 50.87x |
| P/B Ratio | 7.1x |
| ROE | 13.81% |
| ROCE | 24.97% |
| EPS | Rs 6.87 |
| Book Value Per Share | Rs 49.28 |
| Dividend Yield | 0.14% |
SURAKSHA DIAGNOSTIC LIMITED (SURAKSHA) fundamental metrics show P/E 50.87x, P/B 7.1x, ROE 13.81%, ROCE 24.97%. These figures provide context only and are not a buy or sell signal.
SURAKSHA DIAGNOSTIC LIMITED has a market capitalisation of Rs 1750.17 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 50.87x, P/B at 7.1x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 13.81% and ROCE of 24.97%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 6.87, book value per share of Rs 49.28, dividend yield of 0.14%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 44.99x, median ROE of 13.01%, median ROCE of 15.84%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Hospital & Healthcare Services |
| Benchmark Scope | same industry |
| Company P/E Ratio | 50.87x |
| Benchmark Median P/E | 44.99x |
| Benchmark Average P/E | 90.77x |
| Benchmark P/E Range | 0x to 1,601.32x |
| Company P/B Ratio | 7.1x |
| Benchmark Median P/B | 3.65x |
| Company ROE | 13.81% |
| Benchmark Median ROE | 13.01% |
| Company ROCE | 24.97% |
| Benchmark Median ROCE | 15.84% |
| Company Market Capitalisation | Rs 1,750.17 crore |
| Benchmark Median Market Cap | Rs 502.06 crore |
SURAKSHA DIAGNOSTIC LIMITED (SURAKSHA) is classified under sector: Healthcare and industry: Hospital & Healthcare Services.
SURAKSHA DIAGNOSTIC LIMITED (SURAKSHA) has a P/E ratio of 50.87x, which is above the benchmark median of 44.99x, a difference of +13.07%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
SURAKSHA DIAGNOSTIC LIMITED (SURAKSHA) has a ROE of 13.81%, which is above the benchmark median of 13.01%, a difference of +6.15%. SURAKSHA DIAGNOSTIC LIMITED (SURAKSHA) has a ROCE of 24.97%, which is above the benchmark median of 15.84%, a difference of +57.64%.
Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Krsnaa Diagnostics Ltd. | KRSNAA | 1,756.55 | 18.48 | 1.82 | 10.97 | 13.08 |
| Shalby Ltd. | SHALBY | 1,488.91 | 38.07 | 1.47 | 3.48 | 6.88 |
| GUJARAT KIDNEY N SUP SP L | GKSL | 1,431.79 | 91.19 | 5.6 | 68.65 | 63.02 |
| GPT Healthcare Ltd. | GPTHEALTH | 1,361.29 | 28.64 | 4.8 | 16.32 | 23.06 |
| Dr Agarwals Eye Hospital Ltd. | DRAGARWQ | 2,544.8 | 33.39 | 6.88 | 25.22 | 29.21 |
SURAKSHA DIAGNOSTIC LIMITED (SURAKSHA) has a P/E ratio of 50.87x compared with the displayed peer median of 33.39x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 13.81% compares with a peer median of 16.32% across the companies shown in the table. ROCE stood at 24.97% versus the displayed peer median of 23.06%, providing a capital-efficiency comparison. SURAKSHA DIAGNOSTIC LIMITED (SURAKSHA) has a market capitalisation of Rs 1,750.17 crore. Among the 5 peers shown, 2 have a larger market capitalisation.
Why Investors Are Watching SURAKSHA
- SURAKSHA 52 Week High Streak is now in a second straight session near the yearly peak.
- The stock has moved 5.18% across the streak, which is the key cumulative read.
- The current price of Rs 353.45 is just below the latest 52-week high of Rs 354.05.
- P/E and P/B remain above industry medians in the healthcare peer set.
- ROCE of 24.97% stands out versus the same-industry benchmark.
About SURAKSHA DIAGNOSTIC LIMITED
SURAKSHA DIAGNOSTIC LIMITED is a healthcare company in the Hospital & Healthcare Services industry. The stock is listed on NSE and BSE under the symbol SURAKSHA. In market-cap terms, the company is valued at Rs 1,750.17 crore, and its latest metrics show a mix of earnings, book-value and capital-efficiency measures that investors commonly track in the diagnostics and hospital space.
For readers following SURAKSHA stock news, the company sits in a segment where valuation, return ratios and operating visibility often matter alongside price behaviour. That is why the current 52-week high streak is best read together with the company’s financial ratios and industry benchmark context.
Track SURAKSHA on Univest
Track SURAKSHA on Univest for the latest SURAKSHA share price today, stock analysis, market cap updates and company news. You can also follow the broader list of 52 Week High Stocks and keep an eye on how the stock behaves near its yearly high over the next sessions.
For quick monitoring, the Univest stock page keeps the latest market snapshot in one place so readers can compare the daily move, the streak context and the valuation set-up without losing the wider sector view.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What does SURAKSHA 52 Week High Streak mean?
Ans. It means SURAKSHA has traded within 2% of its 52-week high for consecutive sessions. In this case, the streak has lasted for a second straight session, which makes the current price action more notable than a single-day move.
How long is the current SURAKSHA streak?
Ans. The current SURAKSHA streak is two consecutive sessions. The stock has stayed within 2% of its 52-week high on both days, and the cumulative move across that streak is 5.18%.
What is the latest 52-week high for SURAKSHA?
Ans. The latest 52-week high mentioned in the market data is Rs 354.05. The current price of Rs 353.45 remains very close to that level, which is why the stock is being tracked as a near-high streak.
Did SURAKSHA hit a new all-time high today?
Ans. No statement can be made about an all-time high from the numbers provided here. The event being tracked is a 52-week high streak, which is different from a lifetime or record high.
What is driving the SURAKSHA share price today?
Ans. The latest figures confirm that the SURAKSHA share price is trading near its yearly high, but they do not establish a company-specific catalyst. The article therefore treats the price pattern as confirmed market behaviour, not a named reason.
Is SURAKSHA expensive compared with peers?
Ans. SURAKSHA trades at a P/E of 50.87 and a P/B of 7.1, both above the industry medians in the latest healthcare peer set. That makes the valuation richer than the median benchmark, even as profitability ratios remain relevant.
What should investors watch next in SURAKSHA stock analysis?
Ans. Investors should watch whether the stock stays near the yearly high, how the next few sessions develop, and whether fundamentals continue to support the current valuation. The streak itself is factual; the next business trigger is not yet confirmed.
How does SURAKSHA compare with other healthcare peers?
Ans. SURAKSHA’s market cap is similar to several hospital and healthcare services peers, while its valuation ratios are above many of them. Its ROCE is also stronger than the industry median, which makes the peer comparison more balanced.
Track SURAKSHA DIAGNOSTIC LIMITED (SURAKSHA) Share Price on Univest
Use SURAKSHA DIAGNOSTIC LIMITED (SURAKSHA) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.
